Active Motif and EpiCypher Execute Cross-Licensing Agreement and End Ongoing Litigation Involving Targeted Transposition/CUT&Tag Technology for Epigenomics
CARLSBAD, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 1, 2022 /PRNewswire/ -- CUT&Tag is a targeted transposition technique that allows high-resolution genomic mapping of histone modifications and chromatin-associated proteins through the precise insertion of DNA sequences into the genome using the Tn5 transposase enzyme. EpiCypher and Active Motif each own or control patents covering complementary aspects of targeted transposition....
Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
CARLSBAD, Calif., Aug. 1, 2022 /PRNewswire/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). The innovations underlying these patents allow mechanistic, translational, and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of...
PERSISTENT LOSS OF SMELL DUE TO COVID-19 CLOSELY CONNECTED TO LONG-LASTING COGNITIVE PROBLEMS
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022 Also, ICU Stay May Double Risk of Dementia in Older Adults SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- New insights into factors that may predict, increase or protect against the impact of COVID-19 and the pandemic on memory and thinking skills were revealed by multiple studies...
Global Fund Reports Significant Progress in Breaking Down Human Rights-Related Barriers to HIV and TB Services
MONTREAL, Aug. 1, 2022 /PRNewswire/ -- A new report released by the Global Fund today at the 24th International AIDS Conference unveils key findings of the activities supported by the Global Fund's Breaking Down Barriers initiative, a groundbreaking program launched in 2017 to provide intensive financial and technical support to 20 countries* to address...
Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior...
SAN FRANCISCO and SUZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Laekna Therapeutics, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, jointly...
WPP uncovers the shifting values, priorities and perceptions of Aussies in 2022
Kindness is the most important value for most (81%) Australians Most Australians (63%) fear expressing our honest views online for fear of retribution The pandemic has meant more authentic social media representation, as fewer (-38%) respondents misrepresent their lives since 2018 SYDNEY, Aug. 1, 2022 /PRNewswire/ -- WPP, Australia & New Zealand, today announces the launch of Secrets and...
LIMES Randomised Controlled Trial about Sirolimus Coated Balloon in BTK takes the first Stride: patient enrolment started
Concept Medical Inc., a pioneer in developing drug delivery device platforms for vascular intervention, has announced the initiation of LIMES trial. MÜNSTER, Germany, July 29, 2022 /PRNewswire/ -- LIMES (Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of SiroLIMus Drug Coated Balloon versus Standard Angioplasty for the Treatment of...
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division Operating income turned to profit compared to the last quarter, while investment to R&D continued in the second quarter Immunovant initiated...
HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial
SINGAPORE, July 29, 2022 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with the current conventional histological scoring system, in quantifying treatment-associated changes in Nonalcoholic Steatohepatitis (NASH). AI-DP with Second Harmonic Generation/Two-photon Excitation Fluorescence (SHG/TPEF) was...
Seegene unveils strategies for global expansion at 2022 AACC
Company has taken part in the Annual Scientific Meeting & Clinical Lab Expo since 2007 This year's event showcased its In-life PCR campaign and STARlet-AIOS Seegene also displayed Novaplex™ assays, including a test for detecting the monkeypox virus SEOUL, South Korea, July 29, 2022 /PRNewswire/ -- Seegene Inc. (096530), South Korea's leading...
